280 related articles for article (PubMed ID: 17876769)
1. Post-transplant hepatosplenic T-cell lymphoma successfully treated with HyperCVAD regimen.
Tey SK; Marlton PV; Hawley CM; Norris D; Gill DS
Am J Hematol; 2008 Apr; 83(4):330-3. PubMed ID: 17876769
[TBL] [Abstract][Full Text] [Related]
2. T-cell gamma/delta hepatosplenic lymphoma - prolonged remission induced by aggressive first line treatment.
Procházka V; Papajík T; Jarosová M; Pikalová Z; Indrák K; Tichý M; Kucerová L; Fakan F; Bílý M; Starostka D
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2005 Dec; 149(2):275-6. PubMed ID: 16601770
[TBL] [Abstract][Full Text] [Related]
3. Rare variety of T-cell lymphoma.
Pednekar S; Morge V; Rawal S; Korivi D; Ramteke V; Naik K
J Assoc Physicians India; 2011 Oct; 59():667-8. PubMed ID: 22479752
[TBL] [Abstract][Full Text] [Related]
4. Hepatosplenic gamma-delta T-cell lymphoma as a late-onset posttransplant lymphoproliferative disorder in renal transplant recipients.
Wu H; Wasik MA; Przybylski G; Finan J; Haynes B; Moore H; Leonard DG; Montone KT; Naji A; Nowell PC; Kamoun M; Tomaszewski JE; Salhany KE
Am J Clin Pathol; 2000 Apr; 113(4):487-96. PubMed ID: 10761449
[TBL] [Abstract][Full Text] [Related]
5. Complete remission in advanced blastic NK-cell lymphoma/leukemia in elderly patients using the hyper-CVAD regimen.
Shapiro M; Wasik MA; Junkins-Hopkins JM; Rook AH; Vittorio CC; Itakura H; Frankel MC; Georgala S; Schuster SJ
Am J Hematol; 2003 Sep; 74(1):46-51. PubMed ID: 12949889
[TBL] [Abstract][Full Text] [Related]
6. Hepatosplenic gamma/delta T-cell lymphoma in immunocompromised patients. Report of two cases and review of literature.
Khan WA; Yu L; Eisenbrey AB; Crisan D; al Saadi A; Davis BH; Hankin RC; Mattson JC
Am J Clin Pathol; 2001 Jul; 116(1):41-50. PubMed ID: 11447750
[TBL] [Abstract][Full Text] [Related]
7. Ongoing remission after intensive ALL-type chemotherapy in pediatric intestinal T-cell lymphoma.
Friedrich C; Schrum J; Chott A; Janka-Schaub G; Kabisch H
Pediatr Blood Cancer; 2010 Apr; 54(4):610-2. PubMed ID: 20049930
[TBL] [Abstract][Full Text] [Related]
8. Hepatosplenic gamma/delta T-cell lymphoma in bone marrow. A sinusoidal neoplasm with blastic cytologic features.
Vega F; Medeiros LJ; Bueso-Ramos C; Jones D; Lai R; Luthra R; Abruzzo LV
Am J Clin Pathol; 2001 Sep; 116(3):410-9. PubMed ID: 11554170
[TBL] [Abstract][Full Text] [Related]
9. Burkitt-like post-transplant lymphoproliferative disorder (PTLD) presenting with breast mass in a renal transplant recipient: a report of a rare case.
Law MF; Chan HN; Leung C; Lai HK; Ha CY; Ng C; Yeung YM; Yip SF
Ann Hematol; 2014 Dec; 93(12):2083-5. PubMed ID: 24782123
[No Abstract] [Full Text] [Related]
10. [Microcellular lung carcinoma in patient with hepatosplenic T-cell lymphoma: a case report].
Kalac M; Ostojić S; Gasparov S; Planinc-Peraica A; Dominis M; Jaksić B
Lijec Vjesn; 2006; 128(3-4):76-8. PubMed ID: 16808095
[TBL] [Abstract][Full Text] [Related]
11. Hepatosplenic T cell lymphoma responsive to 2'-deoxycoformycin therapy.
Bennett M; Matutes E; Gaulard P
Am J Hematol; 2010 Sep; 85(9):727-9. PubMed ID: 20652973
[TBL] [Abstract][Full Text] [Related]
12. [Intravascular large B-cell lymphoma with pontine involvement successfully treated with R-hyper-CVAD/R-MTX-Ara-C regimen].
Nakazato T; Suzuki K; Mihara A; Sanada Y; Yoshida S; Kakimoto T
Rinsho Ketsueki; 2010 Feb; 51(2):148-52. PubMed ID: 20379108
[TBL] [Abstract][Full Text] [Related]
13. Hepatosplenic T-cell lymphoma: clinicopathologic, immunophenotypic, and molecular characterization of 17 Chinese cases.
Lu CL; Tang Y; Yang QP; Wang M; Zhao S; Bi CF; Jiang NG; Zhang WY; Liu JP; Xu X; Liu WP
Hum Pathol; 2011 Dec; 42(12):1965-78. PubMed ID: 21683978
[TBL] [Abstract][Full Text] [Related]
14. Hepatosplenic gamma-delta T-cell lymphoma.
Ferreri AJ; Govi S; Pileri SA
Crit Rev Oncol Hematol; 2012 Aug; 83(2):283-92. PubMed ID: 22047938
[TBL] [Abstract][Full Text] [Related]
15. T-cell lymphoma in the parotid region after cardiac transplant: case report.
Mandel L; Surattanont F; Dourmas M
J Oral Maxillofac Surg; 2001 Jun; 59(6):673-7. PubMed ID: 11381393
[No Abstract] [Full Text] [Related]
16. Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine.
Garcia M; Romaguera JE; Inamdar KV; Rassidakis GZ; Medeiros LJ
Cancer; 2009 Mar; 115(5):1041-8. PubMed ID: 19170236
[TBL] [Abstract][Full Text] [Related]
17. [T-cell rich B-cell lymphoma associated with hemophagocytic syndrome].
Dommann-Scherrer C; Zimmermann D; Hassam S; Odermatt BF; Risti B; Maurer R
Verh Dtsch Ges Pathol; 1992; 76():122-5. PubMed ID: 1283241
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.
Wang M; Fayad L; Cabanillas F; Hagemeister F; McLaughlin P; Rodriguez MA; Kwak LW; Zhou Y; Kantarjian H; Romaguera J
Cancer; 2008 Nov; 113(10):2734-41. PubMed ID: 18973182
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic T-lymphocyte differentiation and cytogenetic alterations in gammadelta hepatosplenic T-cell lymphoma and posttransplant lymphoproliferative disorders.
Salhany KE; Feldman M; Peritt D; Nowell PC
Blood; 1997 May; 89(9):3490-1. PubMed ID: 9129060
[No Abstract] [Full Text] [Related]
20. Hepatosplenic gammadelta T-cell lymphoma successfully treated with a combination of alemtuzumab and cladribine.
Jaeger G; Bauer F; Brezinschek R; Beham-Schmid C; Mannhalter C; Neumeister P
Ann Oncol; 2008 May; 19(5):1025-6. PubMed ID: 18375525
[No Abstract] [Full Text] [Related]
[Next] [New Search]
